News

Novartis says CTL019 achieved remission in 82% of patients

Sunday 4 December 2016
Country
United States

Novartis said that its chimeric antigen receptor (CAR) T cell therapy, developed jointly with the University of Pennsylvania, achieved significant disease remission in paediatric and young adult patients with B cell acute lymphoblastic leukaemia.

Jardiance approved for new indication

Sunday 4 December 2016
Country
United States

Boehringer Ingelheim GmbH and Eli Lilly and Company have won a second indication for their jointly developed diabetes drug Jardiance (empagliflozin) which belongs to a new class of drugs known as sodium glucose transporter 2 (SGLT2) inhibitors.

Genome sequenced using hand-held device

Saturday 3 December 2016
Country
United Kingdom

UK researchers have reported sequencing the whole genomes of a human donor and a patient using a hand-held device based on nanopore technology. The device was developed by Oxford Nanopore Technologies Ltd, a venture capital-backed company based in Oxford UK.

Actelion, Johnson & Johnson confirm talks

Saturday 26 November 2016
Country
Switzerland

Switzerland-based Actelion Ltd and Johnson & Johnson Inc have confirmed that they are in discussions about a “potential transaction.” This is the second negotiation involving Actelion in a little over a year.

Eli Lilly Alzheimer’s drug fails

Thursday 24 November 2016
Country
United States

Solanezumab, a monoclonal antibody that was being tested in patients with mild dementia due to Alzheimer’s disease, won’t be submitted for registration following the drug’s failure to meet its primary endpoint in a Phase 3 trial, Eli Lilly and Company announced on 23 November.

Two more deaths in Juno immunotherapy trial

Thursday 24 November 2016
Country
United States

Juno Therapeutics Inc of the US suspended a trial of its chimeric antigen receptor (CAR) T cell therapy for leukaemia for a second time on 23 November following the deaths of two patients from cerebral edema.

Kite outlines regulatory plans

Wednesday 23 November 2016
Country
United States

Kite Pharma Inc plans to make a US regulatory submission for its lead chimeric antigen receptor (CAR) T cell therapy for patients with non-Hodgkin lymphoma starting at the end of December. Following talks with the Food and Drug Administration, the US company announced in early November that it will make a rolling regulatory submission.

Novartis acquires Selexys

Monday 21 November 2016
Country
Switzerland

Novartis has taken steps to broaden its portfolio of drugs treating haematologic disorders with the acquisition of Selexys Pharmaceuticals Corp of the US which has a product for treating a complication of sickle cell disease that recently completed Phase 2.

Safety mechanism for autoimmunity

Sunday 20 November 2016
Country
Sweden

Researchers at the Karolinska Institutet have identified a previously unknown safety mechanism in the immune system that protects the body from autoimmune diseases. The discovery may be the key to countering autoimmune diseases, such as systemic lupus erythematosus (SLE), they contend.